BG106096A - Fap - активирани противотуморни съединения - Google Patents
Fap - активирани противотуморни съединения Download PDFInfo
- Publication number
- BG106096A BG106096A BG106096A BG10609601A BG106096A BG 106096 A BG106096 A BG 106096A BG 106096 A BG106096 A BG 106096A BG 10609601 A BG10609601 A BG 10609601A BG 106096 A BG106096 A BG 106096A
- Authority
- BG
- Bulgaria
- Prior art keywords
- compound
- group
- formula
- cyt
- cytotoxic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1019—Tetrapeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13413699P | 1999-05-14 | 1999-05-14 | |
| PCT/EP2000/004261 WO2000071571A2 (en) | 1999-05-14 | 2000-05-11 | Fap-activated anti-tumor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG106096A true BG106096A (bg) | 2002-05-31 |
Family
ID=22461925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG106096A Pending BG106096A (bg) | 1999-05-14 | 2001-11-09 | Fap - активирани противотуморни съединения |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US6613879B1 (ja) |
| EP (1) | EP1180116A2 (ja) |
| JP (1) | JP3607201B2 (ja) |
| KR (1) | KR20020030270A (ja) |
| CN (1) | CN1213058C (ja) |
| AR (1) | AR033792A1 (ja) |
| AU (1) | AU777521B2 (ja) |
| BG (1) | BG106096A (ja) |
| BR (1) | BR0010564A (ja) |
| CA (1) | CA2369933A1 (ja) |
| CO (1) | CO5170516A1 (ja) |
| CZ (1) | CZ20014097A3 (ja) |
| EA (1) | EA005204B1 (ja) |
| EE (1) | EE200100600A (ja) |
| HK (1) | HK1048642B (ja) |
| HU (1) | HUP0202367A3 (ja) |
| IL (1) | IL145798A0 (ja) |
| MX (1) | MXPA01011401A (ja) |
| MY (1) | MY125939A (ja) |
| NO (1) | NO20015536L (ja) |
| NZ (1) | NZ516075A (ja) |
| PL (1) | PL351680A1 (ja) |
| SK (1) | SK16452001A3 (ja) |
| TW (1) | TWI248444B (ja) |
| UA (1) | UA73506C2 (ja) |
| WO (1) | WO2000071571A2 (ja) |
| YU (1) | YU80901A (ja) |
| ZA (1) | ZA200109151B (ja) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA02009019A (es) | 2000-03-15 | 2003-02-12 | Du Pont Pharm Co | Farmacos antineoplasticos de objetivo, que se desdoblan por la peptidasa y su uso terapeutico. |
| GB0027552D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
| GB0027551D0 (en) * | 2000-11-10 | 2000-12-27 | Boehringer Ingelheim Pharma | Anti-tumor compounds |
| BR0210149A (pt) * | 2001-05-09 | 2004-06-29 | Newbiotics Inc | Pródrogas ativadas por deformilase de peptìdeo |
| US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| EP1333033A1 (en) * | 2002-01-30 | 2003-08-06 | Boehringer Ingelheim Pharma GmbH & Co.KG | FAP-activated anti-tumor compounds |
| US20030211979A1 (en) * | 2002-01-30 | 2003-11-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | FAP-activated anti-tumor compounds |
| US20050096254A1 (en) * | 2002-04-18 | 2005-05-05 | Sergeeva Maria V. | Peptide deformylase activated prodrugs |
| WO2003094972A2 (en) * | 2002-05-10 | 2003-11-20 | Boehringer Ingelheim Pharma Gmbh & Co Kg | Fap-activated anti-tumor prodrugs |
| US20040033957A1 (en) * | 2002-05-10 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | FAP-activated anti-tumor prodrugs |
| US20040001801A1 (en) * | 2002-05-23 | 2004-01-01 | Corvas International, Inc. | Conjugates activated by cell surface proteases and therapeutic uses thereof |
| AU2003290779A1 (en) * | 2002-11-14 | 2004-06-03 | Celmed Oncology (Usa), Inc. | Peptide deformylase activated prodrugs |
| GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| US7638638B2 (en) | 2003-05-14 | 2009-12-29 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| US7687638B2 (en) | 2004-06-04 | 2010-03-30 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
| WO2006073167A1 (ja) * | 2005-01-07 | 2006-07-13 | Ono Pharmaceutical Co., Ltd. | ピロリジン誘導体 |
| US7399869B2 (en) | 2005-05-19 | 2008-07-15 | Genentech, Inc. | Fibroblast activation protein inhibitor compounds and methods |
| EP1963537A4 (en) * | 2005-12-14 | 2009-11-11 | Ludwig Inst For Cancer Res Ltd | METHOD FOR DIAGNOSING RHEUMATOID ARTHRITIS BY DETERMINING FIBROBLASTIC SYNOVIOCYTES FOR FIBROBLAST ACTIVATION PROTEIN |
| US20100047170A1 (en) * | 2006-01-05 | 2010-02-25 | Denmeade Samuel R | Peptide Prodrugs |
| WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2008005479A2 (en) * | 2006-07-06 | 2008-01-10 | University Of Wyoming | Charge reversible polymers |
| US20100184706A1 (en) * | 2007-03-20 | 2010-07-22 | Bachovchin William W | Fap-activated chemotherapeutic compounds, and methods of use thereof |
| ES2571217T3 (es) * | 2008-09-12 | 2016-05-24 | Cadila Pharmaceuticals Ltd | Profármacos de sitagliptina |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| US20150335761A1 (en) * | 2012-02-16 | 2015-11-26 | Raymond Firestone | Compositions and methods for contraception |
| PL2938360T3 (pl) * | 2012-12-28 | 2020-05-18 | Cobiores Nv | Minimalnie toksyczne proleki |
| AU2014253584B2 (en) * | 2013-04-19 | 2017-02-02 | Jinan University | Vinca Alkaloid Derivatives, Preparation Method therefor and Application thereof |
| PT3066091T (pt) | 2013-11-05 | 2019-07-11 | Astrazeneca Ab | Pro-farmacos de antagonista de nmda |
| US9737556B2 (en) * | 2014-06-13 | 2017-08-22 | Trustees Of Tufts College | FAP-activated therapeutic agents, and uses related thereto |
| EP4299134A3 (en) | 2014-06-13 | 2024-03-27 | Bach Biosciences, LLC | Fap-activated therapeutic agents, and uses related thereto |
| CN105524141B (zh) * | 2015-11-12 | 2019-11-26 | 中山大学 | 一种FAPa激活式肿瘤诊断多肽磁珠复合物的制备与应用 |
| EP3222292A1 (en) | 2016-03-03 | 2017-09-27 | Heidelberg Pharma GmbH | Amanitin conjugates |
| CN107043456B (zh) * | 2017-04-19 | 2019-05-17 | 川北医学院 | 对氧环己酮与l-苯丙氨酸氮芥共聚物及其应用 |
| CN110128501A (zh) * | 2019-05-21 | 2019-08-16 | 北京海美源医药科技有限公司 | 一种靶向fap酶的喜树碱类化合物及其制备方法和应用 |
| CN110128506B (zh) * | 2019-05-22 | 2021-03-30 | 中国药科大学 | 一种寡肽及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3915800A (en) * | 1972-03-30 | 1975-10-28 | Kelco Co | Polysaccharide and bacterial fermentation process for its preparation |
| FR2546163B1 (fr) | 1983-05-16 | 1987-10-09 | Centre Nat Rech Scient | Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application |
| US5047401A (en) * | 1985-09-09 | 1991-09-10 | Board Of Regents, The University Of Texas System | Use of dipeptide alkyl esters to treat GVHD |
| EP0255341B1 (en) | 1986-07-29 | 1993-02-03 | Sunstar Kabushiki Kaisha | Reagent for testing periodontal diseases |
| US5776892A (en) * | 1990-12-21 | 1998-07-07 | Curative Health Services, Inc. | Anti-inflammatory peptides |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5866679A (en) | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
| DE19512484A1 (de) * | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
| EP0855910A4 (en) | 1995-10-18 | 2000-07-05 | Merck & Co Inc | CONJUGATES USEFUL FOR TREATING BENIN PROSTATIC ADENOMA |
| CA2256669A1 (en) | 1996-05-29 | 1997-12-04 | Prototek, Inc. | Prodrugs of thalidomide and methods for using same as modulators of t-cell function |
| US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
| WO1998013059A1 (en) | 1996-09-27 | 1998-04-02 | Bristol-Myers Squibb Company | Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells |
| DE19640970A1 (de) * | 1996-10-04 | 1998-04-16 | Bayer Ag | Modifizierte Cytostatika |
| DE69942128D1 (de) | 1998-12-11 | 2010-04-22 | Coulter Pharm Inc | Prodrugs und verfahren zu deren herstellung |
| EP1176985A2 (en) | 1999-04-28 | 2002-02-06 | Vectramed, Inc. | Enzymatically activated polymeric drug conjugates |
-
2000
- 2000-04-21 US US09/553,800 patent/US6613879B1/en not_active Expired - Lifetime
- 2000-05-11 EE EEP200100600A patent/EE200100600A/xx unknown
- 2000-05-11 SK SK1645-2001A patent/SK16452001A3/sk unknown
- 2000-05-11 EP EP00952966A patent/EP1180116A2/en not_active Withdrawn
- 2000-05-11 KR KR1020017014480A patent/KR20020030270A/ko not_active Application Discontinuation
- 2000-05-11 PL PL00351680A patent/PL351680A1/xx not_active Application Discontinuation
- 2000-05-11 HU HU0202367A patent/HUP0202367A3/hu unknown
- 2000-05-11 EA EA200101155A patent/EA005204B1/ru not_active IP Right Cessation
- 2000-05-11 NZ NZ516075A patent/NZ516075A/xx unknown
- 2000-05-11 MX MXPA01011401A patent/MXPA01011401A/es active IP Right Grant
- 2000-05-11 CA CA002369933A patent/CA2369933A1/en not_active Abandoned
- 2000-05-11 YU YU80901A patent/YU80901A/sh unknown
- 2000-05-11 BR BR0010564-3A patent/BR0010564A/pt not_active Expired - Fee Related
- 2000-05-11 JP JP2000619826A patent/JP3607201B2/ja not_active Expired - Fee Related
- 2000-05-11 IL IL14579800A patent/IL145798A0/xx unknown
- 2000-05-11 CO CO00034117A patent/CO5170516A1/es not_active Application Discontinuation
- 2000-05-11 WO PCT/EP2000/004261 patent/WO2000071571A2/en not_active Application Discontinuation
- 2000-05-11 CZ CZ20014097A patent/CZ20014097A3/cs unknown
- 2000-05-11 CN CNB008075387A patent/CN1213058C/zh not_active Expired - Fee Related
- 2000-05-11 AU AU65591/00A patent/AU777521B2/en not_active Ceased
- 2000-05-12 AR ARP000102287A patent/AR033792A1/es not_active Suspension/Interruption
- 2000-05-12 TW TW089109087A patent/TWI248444B/zh active
- 2000-05-12 MY MYPI20002102A patent/MY125939A/en unknown
- 2000-11-05 UA UA2001128659A patent/UA73506C2/uk unknown
-
2001
- 2001-11-06 ZA ZA200109151A patent/ZA200109151B/en unknown
- 2001-11-09 BG BG106096A patent/BG106096A/bg active Pending
- 2001-11-13 NO NO20015536A patent/NO20015536L/no not_active Application Discontinuation
-
2003
- 2003-02-06 HK HK03100836.5A patent/HK1048642B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6613879B1 (en) | FAP-activated anti-tumour compounds | |
| US20030055052A1 (en) | FAP-activated anti-tumor compounds | |
| US20020155565A1 (en) | FAP-activated anti-tumor compounds | |
| JP2005523264A (ja) | Ｆａｐ活性化抗腫瘍化合物 | |
| EP1144011B1 (en) | Prodrug compounds and process for preparation thereof | |
| JP2004501875A (ja) | トリペプチドプロドラッグ化合物 | |
| JP2004510702A (ja) | イソロイシンを有するプロドラッグ化合物 | |
| SK57399A3 (en) | Conjugates useful in the treatment of prostate cancer | |
| WO2002038590A1 (en) | Fap-alpha-activated anti-tumor compounds | |
| US20030232742A1 (en) | FAP-activated anti-tumor compounds | |
| CN113507961A (zh) | FAPα特异性的双环肽配体 | |
| JP2023518954A (ja) | Ｎｇｒコンジュゲート及びその使用 | |
| EP1506221A2 (en) | Fap-activated anti-tumor prodrugs | |
| US20040033957A1 (en) | FAP-activated anti-tumor prodrugs | |
| US20030211979A1 (en) | FAP-activated anti-tumor compounds | |
| WO2002038591A1 (en) | Fap-activated anti-tumor compounds | |
| WO2002038187A1 (en) | Fap-activated anti-tumour prodrug | |
| AU714288B2 (en) | Novel peptides |